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exacerbates abnormal behavior in a mouse
model of tauopathy
Erica Barini1†, Odetta Antico1†, Yingjun Zhao2,3, Francesco Asta1, Valter Tucci1, Tiziano Catelani4, Roberto Marotta4,
Huaxi Xu2,3 and Laura Gasparini1,5*
Abstract
Background: Alzheimer disease (AD) and other tauopathies develop cerebral intracellular inclusions of
hyperphosphorylated tau. Epidemiological and experimental evidence suggests a clear link between type 2
diabetes mellitus and AD. In AD animal models, tau pathology is exacerbated by metabolic comorbidities,
such as insulin resistance and diabetes. Within this context, anitidiabetic drugs, including the widely-prescribed
insulin-sensitizing drug metformin, are currently being investigated for AD therapy. However, their efficacy for
tauopathy in vivo has not been tested.
Results: Here, we report that in the P301S mutant human tau (P301S) transgenic mouse model of tauopathy,
chronic administration of metformin exerts paradoxical effects on tau pathology. Despite reducing tau
phosphorylation in the cortex and hippocampus via AMPK/mTOR and PP2A, metformin increases insoluble tau
species (including tau oligomers) and the number of inclusions with β-sheet aggregates in the brain of P301S
mice. In addition, metformin exacerbates hindlimb atrophy, increases P301S hyperactive behavior, induces tau
cleavage by caspase 3 and disrupts synaptic structures.
Conclusions: These findings indicate that metformin pro-aggregation effects mitigate the potential benefits
arising from its dephosphorylating action, possibly leading to an overall increase of the risk of tauopathy in elderly
diabetic patients.
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Background
Intraneuronal inclusions made of filaments of hyper-
phosphorylated microtubule-associated tau protein are
neuropathological hallmarks of a subset of neurodegen-
erative diseases termed tauopathies, a class that includes
Alzheimer Disease (AD), corticobasal degeneration, pro-
gressive parasupranuclear palsy and frontotemporal
dementia. In AD, tau inclusions co-exist with extracellu-
lar plaques of beta-amyloid (Aβ), another pathological
hallmark of the disease. The levels of Aβ peptides and
tau species, including total tau and phospho-tau, are altered
in the cerebrospinal fluid (CSF) of subjects at risk for AD
several years before putative onset of clinical symptoms
[1]. However, only the severity of tauopathy strongly
correlates with cognitive impairment in patients [2].
The progression of cerebral tau pathology appears to
be influenced by several risk factors and comorbidities,
including diabetes and insulin resistance. Patients with
type-2 diabetes mellitus (T2DM) develop cognitive
impairment and have an increased risk of developing
AD (reviewed in refs. [3, 4]). Impaired cerebral glucose
metabolism is also detected at early stages in AD [5] and
insulin resistance occurs in the brain of some patients
with AD independently of diabetes [6]. Further, molecu-
lar markers of insulin resistance co-localize with tau
inclusions in AD brain [7], suggesting that impaired
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insulin signaling may be a key factor in the AD patho-
physiological cascade. Considerable experimental and
clinical data support this view: insulin signaling and in-
sulin resistance affect the physiopathology of tau. Specif-
ically, insulin transiently regulates tau phosphorylation
in cultured neurons [8, 9], while reduced insulin signal-
ing increases tau phosphorylation both in cultured neur-
onal cells [10] and in vivo models of insulin resistance
and T2DM [4].
Within this context, the use of antidiabetic drugs has
been proposed as potential therapy for AD [11]. Among
these drugs, metformin is widely used for the treatment
of T2DM, due to its safety profile and low cost. Albeit
still controversial, there is experimental evidence that
metformin may have beneficial effects on cognition. In
rats fed with high-fat diet, metformin significantly atten-
uated insulin resistance and reverts the cognitive impair-
ment induced by metabolic dysfunction [12]. However,
other groups reported that metformin has no effect on
specific cognitive tasks, such as behavioral flexibility,
performance in the Barnes maze or fear conditioning in
rodents with insulin resistance [13, 14]. Still, metfor-
min improves cognitive function in experimental
models unrelated to metabolic dysfunction such as
the pentylentetrazole-induced kindling [15] and the
haloperidol-induced catalepsy in adult mice [16],
suggesting that some of its actions may be unrelated
to its insulin-sensitizing properties. When applied for
a few hours to neurons in vitro, metformin induces
tau dephosphorylation either in basal condition [17]
or after inducing insulin resistance [10]. However, in
the db/db mouse model of insulin resistance, metfor-
min dephosphorylates endogenous murine tau without
affecting glycemia and metabolic parameters, suggest-
ing that the effects on tau may be independent from
the drug’s insulin-sensitizing action [14]. Nevertheless,
it remains unknown whether in the absence of insulin
resistance or diabetes, chronic treatment with metfor-
min ameliorates tau pathology and behavioral per-
formance in a transgenic model of neurodegenerative
tauopathy in vivo.
To investigate this central question, we chronically
administered metformin to the P301S mutant human
tau transgenic (P301S) mouse, which develops tau inclu-
sions throughout the central nervous system, neuronal
loss [18, 19] and behavioral deficits [20]. Chronic met-
formin treatment reduces tau phosphorylation in the
cortex and hippocampus of P301S mice by inducing pro-
tein phosphatase 2A (PP2A) expression via the AMPK/
mTOR pathway. Paradoxically, metformin promotes the
aggregation of recombinant tau in vitro and when given
chronically to P301S mice, increases both the cortical
amount of insoluble tau species (including tau oligo-
mers) and the number of inclusions with β-sheet
secondary structure. This dual action of metformin on
tau pathology exacerbates neurodegeneration-induced
hindlimb atrophy and hyperactive behavior in P301S
mice. Metformin also activates caspase 3, increases tau
cleavage by caspase 3 and disrupts synaptic structures.
This work suggests that in subjects at risk for AD and
tauopathy, metformin’s pro-aggregation effects may miti-
gate its beneficial actions on tau phosphorylation: cau-
tion is thus warranted for metformin application in
chronic therapies in elderly diabetic patients.
Results
P301S mice show neither peripheral nor brain insulin
resistance
We first investigated whether brain tauopathy is associ-
ated with peripheral or central insulin resistance. We ex-
amined peripheral glucose homeostasis using the intra-
peritoneal glucose tolerance test (IPGTT) and insulin
tolerance test (ITT). For IPGTT, after fasting, mice were
challenged with a glucose bolus and glycemia was moni-
tored over 2 h. In both P301S transgenic and wild type
(WT) non-transgenic mice, glycemia peaked within
15 min from the challenge, reached similar levels at all
time points, and returned to baseline after 2 h (Fig. 1a),
displaying a similar AUC for both transgenic and non-
transgenic mice (Fig. 1b). In the ITT, in WT, glycemia
quickly declined from the baseline of 134.2 ± 11.2 mg/dl
to 80.0 ± 6.0 mg/dl 15 min after insulin injection and
started recovering 60 min later, reaching values compar-
able to baseline after 2 h. In P301S and WT mice,
glycemic values and AUC were similar (Fig. 1c, d).
To test brain insulin resistance, we measured cortical
levels of glucose and insulin and analyzed the expression
and activation of the insulin receptor (IR) and its down-
stream signaling molecules IR scaffold-1 (IRS1), protein
kinase B (AKT) and mammalian target of rapamycin
(mTOR). In the cortex of adult P301S and WT mice,
levels of both glucose and insulin were similar (Fig. 1e, f ).
To assess IR expression, we evaluated its primary transla-
tion product IRβ at the mRNA level, and its protein pre-
cursor (IR precursor) and β subunit (IRβ). Levels of IRβ
mRNA (Additional file 1: Figure S1A), IR precursor
(Additional file 1: Figure S1B, C), and IRβ protein
(Fig. 1g, h) were similar in P301S and age-matched
WT mice. Cortical levels of both IRS1 and its form
phosphorylated on Serine 616 (p[S616]IRS1), which
indicates insulin resistance [6], were also similar in
P301S and WT mice (Additional file 1: Figure S1B, D-E).
Levels of AKT and mTOR and their active forms phos-
phorylated on Serine 473 (p[S473]AKT) and Serine 2448
(p[S2448]mTOR), respectively, were unchanged in P301S
mice cortex (Fig. 1g, h; Additional file 1: Figure S1F-G).
Signaling was similarly unchanged in the hippocam-
pus. In both genotypes, there were comparable levels
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of hippocampal IRβ (IRβ / actin: WT, 1.0 ± 0.2; P301S,
1.5 ± 0.2; P = 0.15; Student t-test), IR precursor (IR
precursor / actin: WT, 1.0 ± 0.1; P301S, 0.8 ± 0.1; P = 0.1,
Student t-test), AKT (AKT / tubulin: WT, 1.0 ± 0.2;
P301, 1.4 ± 0.2; P = 0.2, Student t-test), p[S473]AKT
(p[S473]AKT / AKT: WT, 1.0 ± 0.1; P301S, 0.9 ± 0.05;
P = 0.4, Student t-test), and mTOR (mTOR / tubulin:
WT, 1.0 ± 0.2; P301S, 1.1 ± 0.2; P = 0.15; Student t-test).
Overall, these results indicate that in P301S mice,
neither peripheral nor central insulin resistance associate
with brain tauopathy.
Metformin reduces tau phosphorylation in the brain of
P301S mice
To investigate how metformin modulates tau pathology
in vivo, we treated P301S mice with or without metfor-
min for 4 months and analyzed levels of tau and its
phosphorylation state in the cortex and hippocampus.
Currently, metformin is prescribed for T2DM. Consider-
ing that diabetes diagnosis and treatment usually pre-
cede AD onset, we administered metformin according to
a prevention scheme, starting the treatment at 4 weeks
of age, when tauopathy is still minimal and asymptom-
atic in the P301S mouse [21]. The selected dose (2 mg/ml
in the drinking water) achieved metformin plasma levels
comparable to those obtained by therapeutic dosing in
humans (Additional file 1: Table S1) [22] and in P301S
transgenic mice, yielded brain levels comparable to those
achieved in WT non transgenic mice (Additional file 1:
Table S1).
Total tau protein levels were similar in P301S mice
with or without metformin, both in the cortex (Tau5 /
actin: Ctr, 1.0 ± 0.17; Met, 1.03 ± 0.2. P = 0.9, Student
t-test) and hippocampus (Ctr, 1.0 ± 0.1; Met, 1.3 ± 0.1;
P = 0.15, Student t-test). However, tau phosphorylation
was significantly reduced in metformin-treated P301S
mice. Levels of tau phosphorylated on Serine 262 and
the phospho-epitopes recognized by AT8 antibody were
significantly decreased in both the cortex (Fig. 2a-b, d)
and hippocampus (Fig. 2c, e). In the cortex of metformin-
treated P301S mice, phosphorylation on epitopes recog-
nized by PHF1 and AT270 was also decreased (Fig. 2f-g).
Fig. 1 P301S mice show neither peripheral nor brain insulin resistance. a Intraperitoneal glucose tolerance test (IPGTT) in 5 month old WT non-
transgenic and P301S transgenic mice. At time 0, P = 0.9; 15 min, P = 0.29; 30 min, P = 0.33; 60 min, P = 0.3; 120 min, P = 0.26; two-way ANOVA
followed by Holm-Sidak multiple comparison test. P301S, n = 10; WT, n = 12. b IPGTT AUC. P = 0.17; Student t-test. c Insulin tolerance test (ITT) in
5 month old WT non-transgenic and P301S transgenic mice. At time 0, P = 0.09; 15 min, P = 0.95, 30 min, P = 0.69; 45 min, P = 0.73; 60 min, P = 0.24;
90 min, P = 0.11; 120 min, P = 0.22; two-way ANOVA followed by Holm-Sidak multiple comparison test. P301S, n = 12; WT, n = 6. In a and c, data points
represent the average glycemia ± SEM. d ITT AUC. P = 0.50, Student t-test. e-f Glucose concentration (e) and insulin levels (f) in the cortex of 5-month
old P301S and WT mice. n = 6 / group. Glucose and insulin concentrations were normalized to the sample protein content. Bars represent
the average ± SEM. In panel e, P = 0.79; panel f, P = 0.24; Student t-test. g Western blot of mTOR, IRβ and Akt and total tau in the cortex.
Actin and Tubulin were analyzed as a loading control. h Quantitative analysis of protein expression of IRβ (WT, n = 9; P301S, n = 12), AKT
(WT, n = 8; P301S, n = 12) and mTOR (WT, n = 6; P301S, n = 7) in the cortex of 5-month old P301S and WT mice. Protein levels were normalized
to actin. Data are expressed as percentage of WT. Bars represent the average ± SEM. IRβ, P = 0.06; AKT, P = 0.09; mTOR, P = 0.14; Student t-test
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In 5-month old P301S mice, phosphorylated tau accu-
mulates in some, but not all neurons throughout the
brain [18], reaching different degrees of tau pathology in
distinct brain areas. Consistent with this variation, the
number of AT8 positive cells is higher in the prefrontal
cortex than the hippocampus of 5-month old P301S
mice (Fig. 2h, j, k, m). To investigate whether metformin
treatment changes the number of tauopathy-affected
neurons, we counted AT8 immunoreactive (AT8+) cells in
the hippocampus and prefrontal cortex of transgenic mice
treated with or without metformin. Consistent with bio-
chemical findings, in P301S mice treated with metformin,
the number of AT8+ neurons was significantly reduced in
both the prefrontal cortex (Fig. 2h-j) and hippocampus
(Fig. 2k-m). Specifically, in the hippocampus, the number
of AT8+ cells was reduced by 67 % in the granular zone
(Fig. 2n), which contains the majority of hippocampal
AT8+ cells, and by 57 % in the dentate gyrus (Fig. 2o), but
was unchanged in the subiculum (AT8+ cells / 10 mm2:
Ctr, 0.2 ± 0.03; Met, 0.1 ± 0.01; P = 0.1, Student t-test).
These results indicate that in P301S mice, chronic
treatment with metformin decreases the phosphorylation
of tau on several epitopes and reduces the number of
neurons accumulating phospho-tau in the cortex and
hippocampus.
Metformin increases PP2A expression in the brain of
P301S mice
Physiological phosphorylation of tau depends on the
balance between protein kinase and phosphatase activity.
Fig. 2 Metformin treatment reduces tau phosphorylation in vivo. Total tau and phosphorylated tau (pTau) were analyzed in the cortex and
hippocampus of 5 month old P301S mice treated with or without metformin for 4 months. a Western blot of phosphorylated and total tau in the
cortex. Actin was analyzed as a loading control. b-g Quantitative analysis of pTau in the cortex (b, d, f, g) and hippocampus (c, e). Phosphorylated tau
was analyzed using AT8 (b, c), anti-phospho-S262 tau (d, e), PHF-1 (f), AT270 (g) antibodies and normalized to total tau levels. Total tau was analyzed
using Tau5 antibody. Bars represent the average ratio over total tau ± SEM. p < 0.05, Student t-test. Panel b: n = 11 / group. Panel c: Ctr, n = 10; Met,
n = 11. Panel d: Ctr, n = 12; Met, n = 12. Panel e: Ctr, n = 7; Met, n = 6; Panel f-g: Ctr, n = 7; Met, n = 7. h-i Representative fluorescence images
of AT8 immunoreactivity in the cortex of untreated and metformin-treated P301S mice. Scale bars: in H-I, 50 μm; in h’-i’, 150 μm. Panels h’
and i’ are magnification of squared areas in panels h and i. j. AT8 positive (AT8+) cells in the prefrontal cortex. k-l Representative fluorescence images
of AT8 immunoreactivity in hippocampi of untreated and metformin-treated P301S mice. Scale bars: in k-l, 100 μm; in k’-l’, 200 μm. Panels k’ and l’ are
magnification of squared areas in panels k and l, respectively. m-o AT8 positive (AT8+) cells in the hippocampus (m), granular zone (n) and dentate
gyrus (o). Panel j: Ctr, n = 3; Met, n = 4; Panel m-o: Ctr, n = 3; Met, n = 5. In j and m-o, bars represent the average cell number / mm2 ± SEM. *p < 0.05,
**p < 0.01, Student t-test
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Protein phosphatase 2A (PP2A) is the main tau-
targeting protein phosphatase [23], while among ki-
nases, glycogen synthase kinase 3β (GSK3β) plays a
key role in insulin-regulated tau phosphorylation [24].
Metformin acts on both PP2A [17] and GSK3β [10]
in cultured neuronal cells. To investigate how metfor-
min reduces tau phosphorylation in vivo, we analyzed
the protein and mRNA expression of PP2A and the
protein level and activation of GSK3β. After metfor-
min treatment, PP2A protein expression was signifi-
cantly increased in both cortex and hippocampus of
P301S mice (Fig. 3a-c). Specifically, in the cortex,
metformin increased PP2A protein expression by
60 % over untreated transgenic mice (Fig. 3b). To test
whether metformin acts at the level of transcription,
we analyzed PP2A mRNA. In P301S mice, metformin
treatment significantly increased PP2A mRNA in both
cortex (Ctr: 0.69 ± 0.09; Met 1.2 ± 0.15, P = 0.01, Student
t-test) and hippocampus (Ctr: 0.96 ± 0.08; Met: 1.25 ± 0.02;
P = 0.01; Student t-test). We next investigated GSK3β and
its phosphorylation on Serine 9 (p[S9]GSK3β), which
inhibits GSK3β [25]. Chronic treatment with metformin
alters neither GSK3β protein expression nor p[S9]GSK3β
levels (Fig. 3d-e), indicating that metformin does not inhibit
GSK3β activity.
Overall, these findings indicate that in P301S
transgenic mice, chronic treatment with metformin
significantly enhances PP2A expression at mRNA
and protein levels, without changing overall GSK3β
activity.
Fig. 3 Metformin treatment induces PP2A expression, inhibits mTOR and activates AMPK in the brain of P301S mice. Protein levels of PP2A,
GSK3β, pGSK3β, mTOR, S6, phospho-S6 (pS6), AMPK and phospho-AMPK (pAMPK) were analyzed by western blot in the brain of 5 month old
P301S mice treated with or without metformin for 4 months. a Western blot of PP2A in the cortex. Tubulin was analyzed as a loading control.
b-c Quantitative analysis of PP2A in the cortex (b) and hippocampus (c). In panel b: Ctr, n = 10; Met, n = 12. In panel c: Ctr, n = 9; Met, n = 11.
d-e Quantitative analysis of p[S9]GSK3β (d) and GSK3β (e) in the cortex. Ctr, n = 13; Met, n = 12. f Western blot of mTOR in the cortex. Actin was
analyzed as a loading control. g Quantitative analysis of mTOR protein expression. Ctr, n = 7; Met, n = 7. h Western blot of pS6 and S6 in the
cortex. Tubulin was analyzed as a loading control. i-j Quantitative analysis of pS6 (i) and S6 (j). n = 7 / group. k Western blot of pAMPK and AMPK
in the cortex. Tubulin was analyzed as a loading control. l-m Quantitative analysis of AMPK (l) and pAMPK (m). Panel l-m: Ctr, n = 10; Met, n = 12.
Protein expression levels were normalized to tubulin or actin as indicated in the graphs. Levels of phosphorylated proteins were normalized to
the total respective protein. In all graphs, bars represent the average ratio ± SEM. *p < 0.05, **p < 0.01, Student t-test
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Metformin activates the AMPK-mTOR pathway in the
brain of P301S mice
PP2A is regulated by the integration of several intracel-
lular signals, including the insulin signaling pathway [26]
and/or inhibition of mTOR through phosphorylation by
AMPK [27, 28]. We therefore investigated whether
chronic metformin activates any of these pathways in
the brain of P301S mice.
We first analyzed the expression and activation of
AMPK and mTOR. Chronic administration of metfor-
min significantly reduced by 43 % mTOR levels in the
cortex of P301S mice (Fig. 3f-g). To examine mTOR ac-
tivity, we analyzed the total levels and phosphorylation
of S6 (Fig. 3h-j), the substrate of the mTOR downstream
target protein kinase S6 [29]. Treatment with metformin
significantly reduced by 23 % the levels of phospho-S6
(Fig. 3i) without affecting S6 expression (Fig. 3j), indicat-
ing that metformin inhibits mTOR signaling in the brain
of P301S mice.
mTOR is inhibited by AKT phosphorylation on serine
2448 (p[S2448]mTOR) [30] via the insulin signaling
pathway and by AMPK phosphorylation on threonine
2446 [31]. To dissect the mechanisms underlying mTOR
inhibition, we therefore analyzed the insulin signaling
pathway, AMPK and its activation. We first examined
levels of p[S2448]mTOR, IRβ, IRS1, AKT and its
phosphorylated active form (pAKT). There were no
significant differences in the levels of these signaling
molecules in metformin-treated P301S mice (Additional
file 1: Figure S2A-E), arguing against a direct involve-
ment of insulin signaling in metformin’s effects on
mTOR.
We next investigated AMPK expression levels and
phosphorylation on threonine 172 (p[T172]AMPK),
which indicates its activation state [32]. In P301S mice,
chronic treatment with metformin slightly, but signifi-
cantly increased AMPK protein expression (Fig. 3l) and
strongly enhanced its activation (Fig. 3m).
Together, these results suggest that chronic adminis-
tration of metformin inhibits mTOR and activates
AMPK in the brain of P301S mice, without affecting
insulin signaling.
Metformin reduces tau phosphorylation through
activation of PP2A via AMPK/mTOR in vitro
Our results indicate that in the brain of P301S mice,
metformin increases the expression and activation of
AMPK, inhibits mTOR and induces PP2A expression.
To investigate whether these signaling and effector mol-
ecules mediate the effects of metformin on tau phos-
phorylation, we incubated primary cortical neurons with
or without metformin, alone or in combination with
specific inhibitors or activators and analyzed tau phos-
phorylation. Consistent with previous findings [17],
incubation with metformin alone significantly reduced
tau phosphorylation (Fig. 4a) without affecting tau ex-
pression levels (Additional file 1: Figure S3A). The ef-
fects of metformin were independent from insulin.
Despite that levels of phospho-tau were significantly
higher in neurons cultured in the absence of insulin than
in those cultured with insulin, metformin reduced tau
phosphorylation similarly in both cases (Fig. 4a).
To examine PP2A involvement, we treated cortical
neurons with metformin alone or in combination with
the PP2A inhibitor, okadaic acid (OA). As previously
reported [17], OA alone increased the levels of tau phos-
phorylation (Fig. 4b), without changing total tau expres-
sion (tau / Tubulin. Ctr: 1.0 ± 0.08; Met: 0.97 ± 0.4, OA:
0.7 ± 0.08, OA +Met: 0.7 ± 0.06. P = 0.6, One Way
ANOVA). When co-incubated, OA abolished metformin-
induced tau dephosphorylation in primary neurons
(Fig. 4b) indicating that metformin’s effect on tau phos-
phorylation requires PP2A activity.
We next investigated whether AMPK and mTOR ac-
tivity were necessary for metformin’s action on tau phos-
phorylation. For AMPK, we incubated cortical neurons
with metformin alone or in combination with 10 μM
dorsomorphin, an inhibitor of AMPK activity in vitro
[33]. Dorsomorphin strongly inhibited AMPK as judged
by reduced levels of p[T172]AMPK (Fig. 4c) and com-
pletely prevented metformin-induced tau dephosphory-
lation (Fig. 4d), without changing expression levels of
AMPK (Additional file 1: Figure S3B). In neurons
treated with metformin, mTOR was inhibited in the
presence and absence of insulin (Fig. 4e). To examine
the role of mTOR in metformin’s action on tau phos-
phorylation, we inhibited its activity with rapamycin, or
activated it by overexpressing a constitutive active mu-
tant of the mTOR activator Rheb (S16H-Rheb) [34].
Both metformin and rapamycin reduced tau phosphoryl-
ation (Fig. 4f ) and inhibited mTOR, as indicated by de-
creased phospho-S6 levels (Fig. 4g), without affecting S6
protein expression (Additional file 1: Figure S3C). To in-
vestigate whether mTOR is specifically required for
metformin-induced tau dephosphorylation, we trans-
duced primary cortical neurons with lentiviral particles
containing the GFP reporter along with constitutively
active S16H-Rheb. S16H-Rheb activated mTOR in pri-
mary cortical neurons as judged by increased levels of
phospho-S6 (Additional file 1: Figure S3E, Fig. 4h), leaving
unchanged S6 expression (Additional file 1: Figure S3F).
S16H-Rheb expression abolished metformin-induced tau
dephosphorylation (Fig. 4i), without affecting tau expres-
sion levels (Additional file 1: Figure S3G).
Overall, these results indicate that the effects of
metformin on tau phosphorylation occur in an insulin-
independent manner and require the activity of AMPK
and PP2A and inhibition of mTOR.
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Metformin increases insoluble tau and tau inclusions in
the P301S brain and promotes tau oligomeric
aggregation in vitro
We next investigated whether reducing tau phosphoryl-
ation translates into amelioration of tau filamentous
inclusions. We first isolated insoluble tau filaments from
the cortex of 5-month old P301S mice treated with or
without metformin using the sarkosyl extraction. In the
sarkosyl-insoluble fraction of P301S cortex, western
blot analysis using Tau5 antibody revealed major
monomeric tau bands at ≈ 58-60 kDa, a smear at
higher molecular weights with a clear double band at
≈ 115–120 kDa, which is consistent with the molecu-
lar weight of tau dimers. Bands of monomeric tau
were also detected by the AT100 antibody, which rec-
ognized conformations typical of tau filamentous in-
clusions [35]. The amount of insoluble tau, both
monomeric and oligomeric, was significantly increased
Fig. 4 Metformin reduces tau phosphorylation in mouse cortical neurons via the AMPK-mTOR pathway. Primary cortical neurons were incubated
for 6 h with or without 2.5 mM metformin (Met), 10 nM okadaic acid (OA), 10 μM rapamycin (Rapa), and 10 μM dorsomorphin (Dorso) alone or in
combination. All treatments were performed in the absence of insulin, except when specifically indicated. a Quantitative analysis of phospho-tau
(pTau) in cortical neurons treated with or without metformin in the absence or presence of insulin. b Quantitative analysis of pTau in cortical
neurons treated with or without metformin in the absence or presence of okadaic acid. c-d Quantitative analysis of pAMPK (c) and pTau
(d) in cortical neurons treated with or without metformin and dorsomorphin alone or in combination. e Quantitative analysis of pS6 in cortical neurons
treated with or without metformin in the absence or presence of insulin. f-g. Quantitative analysis of pTau (f) and pS6 (g) in cortical neurons treated
with or without metformin and rapamycin. h-i. Quantitative analysis of pS6 (h) and pTau (i) in neurons non-infected (NI), infected with
GFP and S16H-Rheb or GFP alone and treated with metformin. Levels of phosphorylated protein were normalized to levels of respective
proteins. In panels a, b, d, f, and i, pTau and total tau were analyzed using AT8 and Tau5 antibodies, respectively. In all graphs, bars represent
the average ratio ± SEM of 3 independent experiments. *p < 0.05, **p < 0.01, one-way ANOVA followed by Holm-Sidak multiple comparison test
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Fig. 5 (See legend on next page.)
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in metformin-treated P301S mice, with augmented levels
of tau monomers (Fig. 5a-b), dimers (Fig. 5a, c) and
AT100 immunoreactivity (Fig. 5a). We next analyzed
cerebral tau inclusions by immunohistochemistry. Brain
sections were immunostained with the conformation-
dependent anti-tau antibody MC1 [36] or anti-phospho-
tau AT8 antibody and counterstained with the Congo red
analogue FSB. All FSB positive (FSB+) neurons were im-
munoreactive for MC1 antibody (Fig. 5d), but only some
of them were labeled by AT8 (Fig. 5e). We next counted
the FSB+ cells in the prefrontal cortex and hippocampus
of P301S mice, chronically treated with metformin or
untreated. In 5-month old P301S mice, FSB+ inclu-
sions were more abundant in the prefrontal cortex
(62.2 ± 7.7 inclusions / mm2; Fig. 5f) than in the hippo-
campus (2.2 ± 0.6 inclusions / mm2; Fig. 5g). When P301S
mice were treated with metformin, the number of FSB+
inclusions significantly increased by 2.5- and 2.8-fold in
the prefrontal cortex (Fig. 5f) and hippocampus (Fig. 5g),
respectively. Similar results were obtained using Gallyas
silver staining (Fig. 5h-k). The number of Gallyas + cells
was significantly increased in the prefrontal cortex (Fig. 5h,
j) and hippocampus (Fig. 5k) of P301S mice treated with
metformin. Therefore, despite reducing tau phosphoryl-
ation, chronic treatment with metformin significantly
increases the formation of insoluble aggregates with
β-sheet secondary structure in vivo.
We hypothesized that metformin could increase tau
inclusions through direct effects on tau aggregation. To
test this, we evaluated whether metformin promotes ag-
gregation of recombinant P301S mutant human tau
(tauP301S) in vitro using an established heparin-induced
aggregation protocol and the thioflavin T assay. When
incubated in vitro with heparin, recombinant tauP301S
aggregated into fibrils, as detected by both thioflavin T
assay and negative staining transmission electron micros-
copy (Fig. 5l-n). The aggregation process was time-
dependent and quickly reached maximal fluorescence values
(Fig. 5l) due to abundant tau fibrils (Fig. 5l). We then
performed the assay substituting heparin with metformin or
incubating recombinant tauP301S with both heparin and
metformin. With metformin alone, recombinant tauP301S
aggregates in β-sheet-containing species in a time-dependent
manner (Fig. 5l), reaching fluorescence values equal to half
of those obtained with heparin after 14 days in vitro. When
incubated with both metformin and heparin, there was an
increased aggregation lag-time and fluorescence levels were
intermediate between those found with metformin or hep-
arin alone (Fig. 5h). At negative staining TEM, aggregates
obtained with metformin alone had a different structure
compared to those obtained with heparin after 7 days of
incubation (Fig. 5m-n). With heparin, tau forms abundant
filaments (Fig. 5m). In contrast in presence of metformin, we
observed branched aggregates, formed by sub-spherical
units, with a diameter of around 40 nm, aligned in beaded
chains (Fig. 5n). These structures resembled tau protofibrils,
formed by aligned spherical nucleation units (SNUs),
previously described as precursors of tau filaments [37].
We next investigated whether other members of the
biguanide class of antidiabetic drugs with different
chemical structure, i.e., phenformin and buformin, share
the pro-aggregation effect of metformin. After 7 days of
incubation, buformin, but not phenformin, promoted
tau aggregation in vitro (Fig. 5o). There were fewer
(See figure on previous page.)
Fig. 5 Metformin increases the number of tau inclusions in P301S mouse brain in vivo and induces aggregation of recombinant P301S
tau in vitro. a Western blot analysis of tau in the sarkosyl-insoluble cortical fraction from P301S mice treated with or without metformin.
The arrow indicates the bands of tau dimers. Tau was detected using the phosphorylation-and conformation dependent AT100 and Tau5
anti-tau monoclonal antibodies. MemCode was used to control equal loading. b-c Quantitative analysis of monomeric (b) and dimeric (c)
tau in sarkosyl-insoluble fractions of P301S cortex. Densitometric values of tau bands are normalized over MemCode and bars represent
the average ratio ± SEM. P301S, n = 4 / group. d. Representative images of MC1 immunoreactivity (d, d’; green) and FSB (d, d”; light blue)
fluorescence in the cortex of P301S mice. Scale bars: in d, 50 μm; in d’-d”, 100 μm. e Representative images of AT8 immunoreactivity (e, e’; green)
and FSB (e, e”; light blue) fluorescence in the cortex of P301S mice. Scale bars: in e, 50 μm; in e’-e”, 150 μm. f-g FSB+ cells in the prefrontal cortex
(f) and hippocampus (g) of P301S mice. n = 3 / group. Bars represent the average number of FSB+ cells / mm2 ± SEM. **p < 0.01, Student t-test.
h-i. Gallyas silver staining in the cortex of P301S mice untreated (h) or treated with metformin (i). Scale bar 150 μm. j-k. Gallyas+ cells in the
prefrontal cortex (j) and hippocampus (k) of P301S mice. n = 3 / group. Bars represent the average number of Gallyas+ cells / mm2 ± SEM. **p < 0.01,
Student t-test. l. Thioflavin T (ThT) fluorescence of recombinant P301S mutant human tau (P301Stau) aggregated in vitro in the absence (Ctr) or
presence of 37.5 μM heparin (Hep) and/or 30 μM metformin (Met) for 2, 7 and 14 days. Data points represent the average ± SEM from at least 3
independent experiments. m-n. Representative negative staining electron microscopy image of fibrils of recombinant P301Stau aggregated in vitro
for 7 days in presence of heparin (m) or metformin (n). In m, inset shows a high magnification of the squared area. In n, inset shows a high
magnification image of tau aggregates. Scale bars: i-j, 2.5 μm; insets, 0.5 μm. o ThT fluorescence of recombinant P301Stau aggregated in
vitro in the absence (control, Ctr) or presence of 37.5 μM heparin, 30 μM metformin, 30 μM phenformin (Phe) or 30 μM buformin (Buf) for
7 days. Fluorescence values are expressed as arbitrary units and normalized to the control. Bars represent the average ± SEM. **p < 0.01,
one-way ANOVA followed by Holm-Sidak multiple comparison test. p Quantitative analysis of pTau in cortical neurons treated with or with-
out 2.5 mM metformin, 30 μM phenformin and 30 μM buformin. pTau was detected using the AT8 monoclonal antibody and normalized
on total tau detected by Tau5 antibody. Data are expressed as percentage of Ctr. Bars represent the average percentage ± SEM from 2 inde-
pendent experiments. *p < 0.05, **p < 0.01, one-way ANOVA followed by Holm-Sidak multiple comparison test
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aggregates with buformin than with metformin (Fig. 5o).
These results indicate that both metformin and to some
extent buformin act as pro-aggregants on recombinant
tau in vitro.
Considering the possibility that metformin may inter-
act directly with tau, we postulated that the paradoxical
effect on tau phosphorylation could be an artifact due to
an interaction masking the epitope. To test this hypoth-
esis, we spiked cortical lysates from 5-month old P301S
mice with increasing concentrations (2.5–250 μM) of
metformin and analyzed phospho-tau by western blot
with the AT8 antibody. The amount of phospho-tau de-
tected was similar in all samples, irrespective of metfor-
min concentration (Ctr, 1 ± 0.001; 2.5 μM Met, 1.4 ± 0.1;
25 μM Met, 0.8 ± 0.07; 250 μM Met, 1 ± 0.1; P = 0.06,
one-way ANOVA), indicating that potential tau inter-
action and epitope masking do not cause the effects of
metformin on phosphorylation.
Finally, we investigated whether buformin and phen-
formin also affect tau phosphorylation. Due to toxicity,
these biguanides could not be used at concentration
equimolar with metformin and were applied to primary
neurons at 30 μM. At this concentration, phenformin
significantly reduced tau phosphorylation in primary
cortical neurons, while buformin did not have any effect
on tau phosphorylation levels (Fig. 5p).
In summary, metformin concurrently induces tau
dephosphorylation and promotes its aggregation, while
other biguanides retain only one or the other of these
activities.
Metformin treatment enhances hyperactive behavior in
the open field test
Since metformin treatment shows a dual action on tauo-
pathy, by reducing tau phosphorylation and increasing
formation of aggregates with β-sheet secondary struc-
ture, we investigated whether the drug’s effects affected
the behavioral performance in the open field (OF) task.
In the OF, P301S mice display a hyperactive behavior
(i.e., increased distance travelled and speed) without
changes of rearing behavior [20]. Consistently, we found
that 5 month old P301S mice travel an increased
distance, move at higher speed in the OF (Fig. 6a-b) than
WT mice, but have preserved rearing behavior (Fig. 6c).
The hyperactive behavior in the OF has been ascribed to
abnormal activity of both the prefrontal cortex [38] and
hippocampus [39], which in metformin-treated P301S
mice, have an increased burden of inclusions. To investi-
gate whether metformin treatment causes behavioral
changes, P301S mice treated with or without metformin
were subjected to the OF tasks at 4.5 months of age.
At this age, despite extensive brain tauopathy, mice
still eat and drink normally, and move freely. Chronic
treatment with metformin significantly increased the
hyperactive behavior of P301S mice. In metformin-
treated P301S mice, travelled distance and speed were
significantly higher than those of untreated transgenic
mice (Fig. 6d-e). The number of rearings was also sig-
nificantly higher in metformin-treated than untreated
P301S mice (Fig. 6f ). When treated with metformin, 5
out of 9 P301S mice also showed abnormal jumping
activity (number of jumps / 10 min, 3.3 ± 1.36), which
was never observed in untreated P301S mice. The
time spent in the center of the arena was similar in
all treatment groups (Ctr, 0.1 ± 0.04; Met, 0.1 ± 0.01.
P = 0.5, Student t-test).
Overall, these data indicate that chronic treatment
with metformin enhances the hyperactivity typical of
P301S mice.
Metformin treatment exacerbates hindlimb extension
reflex deficit in P301S mice
To examine the effects of metformin treatment on neu-
rodegeneration, we evaluated hindlimb extension reflex,
which is as an index of motor neuron degeneration [40],
throughout the 4-month treatment period. In untreated
P301S mice, leg extension progressively deteriorated
with age until the final stage, when the hindlimbs were
completely retracted with clasped and clenched paws
(Fig. 6g). From 18 weeks of age, P301S mice treated with
metformin scored significantly worse than untreated
transgenic mice (Fig. 6g), indicating that metformin
exacerbates hindlimb neurogenic paralysis.
Metformin treatment induces activation of caspase 3 and
cleavage of tau in primary cortical neurons and in the
P301S mouse brain
Caspase 3 cleaves tau protein at Asp 421 forming a
cleaved-tau (c-Tau) fragment [41, 42], which facilitates
tau filament formation in vitro [41, 42] and in vivo [43]
and has detrimental effects on synaptic structures [44].
To investigate whether metformin affects caspase 3
mediated-tau cleavage and synapses, we treated primary
cortical neurons with metformin for 24 h and examined
active, cleaved caspase 3, the levels of its cleavage
products c-Tau and cleaved-PARP (c-PARP) and the
post-synaptic protein PSD95. In cultured neurons, met-
formin treatment induces caspase 3 activation, increased
levels of c-Tau and c-PARP (Fig. 6h-i) and reduces the
expression of post-synaptic density 95 (PSD95; Fig. 6i).
Through immunocytochemical analysis, we also found
that metformin significantly reduced the number of
clusters with overlapping immunoreactivity for the pre-
synaptic synapsin I and post-synaptic PSD95 proteins
(Fig. 6j), indicating an overall loss of synaptic boutons.
To investigate whether caspase-mediated cleavage of
tau occurs in vivo, we analyzed both total and cleaved
caspase 3 expression in P301S mice chronically treated
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with or without metformin. Caspase 3 total protein
expression was similar across experimental groups
(caspase/tubulin. P301S: Ctr, 0.2 ± 0.06; Met, 0.2 ± 0.03,
P = 0.6, Student t- test). Consistent with previous find-
ings [18], in untreated P301S mice, cells immunoreac-
tive for active cleaved caspase 3 were never observed in
the cortex (Fig. 6k); levels of active cleaved caspase 3 were
barely detectable by western blot. After chronic treatment
with metformin, some cells were immunoreactive for
active caspase 3 in the cortex of P301S mice (Fig. 6k) and
cortical levels of active caspase 3 were significantly
elevated (Fig. 6l). We next examined c-Tau in the soluble
and sarkosyl-insoluble fractions of the cortex of
metformin-treated P301S mice. Levels of soluble c-Tau
were similar in metformin-treated and untreated P301S
mice (Fig. 6m, n). However, in the sarkosyl insoluble
fraction, c-Tau levels were significantly higher in
metformin-treated P301S mice compared to untreated
mice (Fig. 6m, o). To investigate whether chronic met-
formin affects synapses in vivo, we analyzed the expres-
sion of pre- (i.e., synaptophysin and synapsin I) and post-
synaptic (i.e., PSD95) proteins by Western blot. Despite
levels of synapsin I and PSD95 were unchanged, the
expression of synaptophysin was significantly reduced in
P301S mice treated with metformin (Fig. 6p-s). Overall,
these data suggest that in P301S mice, chronic treatment
with metformin induces a small but significant activation of
caspase 3, increased caspase-cleaved tau in the tau
filament-containing sarkosyl-insoluble cerebral fraction and
affects the expression balance of pre-synaptic proteins.
Discussion
Our findings demonstrate that chronic administration of
metformin acts on tau pathology with two distinct
mechanisms. First, it reduces tau phosphorylation in
the cortex and hippocampus, possibly by inducing
PP2A expression via the AMPK/mTOR pathway.
Second, it increases the amount of insoluble tau and
the number of inclusions with β-sheet aggregates in
the brain of P301S mice, likely promoting tau aggre-
gation through direct interaction with the protein.
Further, metformin exacerbates hindlimb atrophy,
increases P301S hyperactive behavior and induces the
activation of caspase 3 with concomitant c-Tau accu-
mulation and synaptic changes.
In AD patients, brain insulin resistance also occurs
independently of diabetes or peripheral insulin resist-
ance [6] and is likely a consequence of Aβ pathology
[6, 45, 46]. Indeed, Aβ oligomers downregulate insulin
receptors in primary cortical neurons [46] and induce
insulin resistance in cultured hippocampal neurons
[45]. Although insulin resistance markers co-localize
with tau inclusions in AD brain [7], the role of tau
pathology in the onset of insulin resistance has been
unclear: our findings indicate that the two are likely
independent. In the P301S mouse, a model of cerebral
tauopathy, we find neither peripheral nor central insulin
resistance. Indeed, peripheral glucose homeostasis, and
brain levels of glucose and insulin are comparable to WT
mice and brain insulin signaling is unaffected.
Metformin acts as an insulin sensitizer and enhances
glucose utilization in peripheral tissues independently
from insulin signaling, via inhibition of mitochondrial
complex I and AMPK activation (reviewed in ref. [47]).
Metformin has hypoglycemic effects only in the context
of diabetes, without affecting glycemia in non-diabetic
subjects [48]. Accordingly, we find that chronic metfor-
min affects neither glycemia nor brain insulin signaling
(See figure on previous page.)
Figure 6 Metformin worsens hindlimb atrophy and hyperactive behavior and induces caspase 3 activation and tau cleavage. a-c Open field test
in 5-month old P301S transgenic mice and age-matched WT non transgenic mice. Distance travelled (a), speed (b) and number of rearings (c) are
shown. Bars represent the average values ± SEM. *p < 0.05, Student t-test. n = 9 / group. d-g, k-s. P301S mice were treated with or without
metformin (Met) for 4 months starting from 1 month of age. d-f. Open field test. Distance travelled (d), speed (e) and rearing (f) are shown.
Bars represent the average values ± SEM. *p < 0.05, Student t-test. Panels d-f: Ctr, n = 11; Met, n = 9. g Hind limb extension test in P301S mice
treated with or without metformin. Data points represent the average score ± SEM. *p < 0.05, two-way ANOVA followed by Holm-Sidak multiple
comparison test. A.U., arbitrary units. Ctr, n = 12; Met, n = 13. h-j. Primary cortical neurons were treated with or without 0.5 mM metformin for
24 h. h-i. Western blot (h) and quantitative analyses (i) of cleaved caspase 3 (c-caspase 3), c-Tau, c-PARP and PSD95. Protein levels were normalized to
actin. Bars represent the average values ± SEM. *p < 0.05, **p < 0.01, Student t-test. n = 3/group. j. Quantification of clusters with overlapping synapsin-I
and PSD95 immunoreactivity. Bars represent the average ± SEM. **p < 0.01, Student t-test. n = 11/group. k Representative confocal maximal projection
images of active c-caspase 3 immunoreactivity (green) in the prefrontal cortex of untreated and metformin-treated P301S mice. Nuclei are
counterstained with Hoechst 33342. Scale bar 10 μm. l Quantitative analysis of active c-caspase 3. c-caspase 3 was analyzed by western
blot and protein levels were normalized to tubulin. Bars represent the average ± SEM. n = 7 / group. *p < 0.05, Student t-test. m Western
blot analysis of cleaved-tau (c-Tau) in the soluble and sarkosyl-insoluble fraction of metformin-treated and untreated P301S mouse cortex.
n-o Quantitative analysis of cleaved Tau (c-Tau) in the soluble (n) and insoluble (o) cortical fraction. c-Tau was analyzed by western blot
and protein levels were normalized to actin (n) or MemCode (o). Bars represent the average ± SEM. Panel n: n = 7 / group. Panel o: n = 3/group.
p Western blot analysis of synapsin I, PSD95, synaptophysin, tubulin and GAPDH in the cortex of P301S mice treated with or without metformin.
q-s. Quantitative analysis of synapsin I (q), PSD95 (r) and synaptophysin (s). Protein levels were analyzed by western bot and normalized to
tubulin or GAPDH. Bars represent the average ± SEM. *p < 0.05, Student t-test. Panel q: n = 7 / group. Panel r: Ctr, n = 13; Met, n = 10. Panel s: Ctr,
n = 13; Met, n = 11
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in P301S mice, which do not have insulin resistance.
Still, metformin has metabolic effects independent of
glucose lowering, including induction of a gene expres-
sion profile typical of caloric restriction and effects on
gut folate microbial metabolism, which have been associ-
ated with an increased lifespan in C. elegans [49, 50],
rats [51] and one, but not another, strain of mice [52].
These findings served as basis to design and propose hu-
man studies investigating the potential use of metformin
to promote healthy aging [53]. Also, in db/db mice, met-
formin reduces the phosphorylation of endogenous mur-
ine tau without affecting the hyperglycemia induced by
insulin resistance [14]. Similarly, in P301S mice, chronic
metformin treatment reduces tau phosphorylation on
several epitopes, without altering glycemic levels, sug-
gesting a disconnection between the drug’s hypoglycemic
action and effects on tau.
Metformin actions on tau phosphorylation may occur
via insulin-independent mechanisms, involving AMPK/
mTOR and PP2A. It has been previously shown that
mTOR plays a key role in modulating tau phosphoryl-
ation in vitro and in vivo. Rapamycin reduces tau phos-
phorylation in primary rodent neurons [17] and in
P301S mice [54, 55] and prevents the hyperphosphoryla-
tion of tau induced either by high glucose diet [56] or
Aβ [57] in the 3XTg-AD mouse. Our results indicate
that mTOR inhibition through AMPK is required to ac-
tivate PP2A and dephosphorylate tau and that this path-
way functions independently of insulin.
Tau phosphorylation is also regulated by several ki-
nases. GSK3β plays a key role in tau phosphorylation
[24] and is inhibited upon activation of different path-
ways, including insulin signaling via AKT [58]. In the
brain of metformin-treated P301S mice, AKT and insulin
signaling are overall unaffected. Accordingly, despite a
small trend toward an increase, inhibition of GSK3β is
not significantly altered in the cortex of P301S mice
treated with metformin, indicating that signaling through
this kinase is not involved in the dephosphorylating action
of metformin.
Surprisingly, despite reducing tau phosphorylation,
chronic metformin increases both the cortical amount of
insoluble tau and the number of cells containing inclu-
sions with β-sheet conformation (positively stained by
FSB and Gallyas) in the cortex and hippocampus of
P301S mice. This is possibly due to different concurring
mechanisms. First, our in vitro results indicate that met-
formin has pro-aggregation effects, leading to the forma-
tion of tau aggregates containing β-sheet secondary
structure as revealed by thioflavin T binding. The thio-
flavin T signal of aggregates induced by metformin is
lower than that of filaments obtained with heparin. This
is possibly due to different ultrastructural features. In
the presence of heparin, tau aggregates in long filaments,
while metformin-induced aggregates appear as tau
protofibrils made of globular oligomers. Consistently,
Western blot analysis of sarkosyl-insoluble tau reveals
that in the cortex of P301S mice treated with metfor-
min there is an increased amount of oligomeric
species, mainly dimers. Metformin-induced globular
aggregates resemble SNUs, which form during the ini-
tial stages of heparin-induced aggregation in vitro and
likely represent tau oligomers or precursors of tau fil-
aments [37]. It has been shown that SNUs bear β-
sheet secondary structure [59]. However, the β-sheet
content is somehow lower than that of heparin-
induced aggregates and is associated with reduced
thioflavin T signal [59]. Within this context, our re-
sults suggest that chronic exposure to metformin may
catalyze the aggregation of tau by promoting the for-
mation of oligomeric species or SNUs.
An alternate mechanism by which metformin may in-
crease the amount of insoluble tau filamentous path-
ology in vivo is through caspase-mediated cleavage of
tau. Caspase 3 cleaves tau at Asp421, forming a trun-
cated form of tau, which aggregates readily and triggers
the assembly of full-length tau into insoluble fragments
[41]. Previous studies demonstrated that caspase 3-
mediated cleavage of tau is an early event in AD tau
pathology [42]. Caspase 3 activation is induced by
appoptosin overexpression, which is increased in the
brain of patients with AD and frontotemporal dementia
with tau inclusions [44]. In living Tg4510 tau transgenic
mice, caspase 3 activation precedes and leads to tau in-
clusions formation [43]. Our findings indicate that in
P301S tau transgenic mice, chronic metformin enhances
this pathological process by inducing activation of
caspase 3 and accumulation of c-Tau in the cerebral
fraction containing insoluble tau filaments.
Among biguanides, only metformin displays a dual
action on tauopathy, i.e. dephosphorylating and pro-
aggregating. The butyl-substituted biguanide, buformin,
retains some pro-aggregating properties, but has no
significant effects on tau phosphorylation in vitro.
Conversely, phenformin, which bears a phenyl-ethyl side
chain, has no pro-aggregating property in vitro, but
maintains tau dephosphorylating properties. It is unclear
how metformin and buformin act on tau aggregation.
Being positively charged at physiological pH, it is
plausible that these molecules electrostatically interact
with tau, neutralizing negative charges and promoting
aggregation. Further studies are warranted to clarify this
fundamental point.
The potential benefits of metformin on cognition and
AD are still controversial. In rodents, metformin
significantly attenuated the cognitive impairment in-
duced by insulin resistance and metabolic dysfunction
as tested with the Morris water maze [12], but has
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no effect on other cognitive tasks, such as behavioral
flexibility [13] or fear conditioning [14]. Still, metformin is
neuroprotective in a mouse model of Huntington disease
[60] and improves cognitive function in experimental
models unrelated to metabolic dysfunction such as
the pentylentetrazole-induced kindling [15] and the
haloperidol-induced catalepsy in adult mice [16]. In
contrast, other studies point to potential adverse ef-
fects of this drug on cognitive performance and AD.
For example, metformin has been associated with im-
paired cognitive performance in elderly patients
(>75 years of age) with diabetes [61]. Further, diabetic
patients taking metformin have an increased risk of
developing AD than those taking other antidiabetic
drugs [62]. Lastly, metformin increases the generation
of Aβ in cultured neurons due to induction of BACE
expression [63]. These findings together with our ob-
servation that metformin may promote tau aggrega-
tion in vivo raise concerns on the potential overall
benefits of metformin for AD and require further in-
vestigation in the elderly population.
Previous intervention studies with drugs targeting
tau pathology report that a parallel decrease in both
phosphorylation and aggregation of tau improves be-
havioral outcomes in the P301S mouse [54, 64]. Our
results instead indicate that metformin’s opposing ac-
tions on tau phosphorylation and aggregation worsens
hindlimb atrophy and the hyperactive behavior of
P301S mice. Such behavioral outcomes suggest that in
AD, metformin may negatively impact on agitation,
which is one of the most disturbing neuropsychiatric
symptoms of AD [65]. However, the behavioral phe-
notypes evaluated in our study are unrelated to cogni-
tive changes associated with AD. Unfortunately, the
strong motor impairment of the P301S transgenic
mouse limits the possibility of investigating the effects
of tauopathy on cognitive domains. Thus, further
studies are warranted to fully clarify the role of tau
aggregates and/or potential tau-unrelated actions of
metformin on cognition in other transgenic models of
tauopathy with cognitive deficits and normal motor
function, such as the Tg4510 mouse [66].
Conclusions
Our findings indicate that metformin pro-aggregation ef-
fects mitigate the potential benefits arising from its de-
phosphorylating action. Metformin is the most widely
prescribed antidiabetic drug, accounting for about 50 %
of prescriptions for non-insulin antidiabetic drugs in
2012 [67]. In the elderly population, there is a high
degree of AD and T2DM comorbidity due to the high
incidence of these pathological conditions during aging
[68, 69] and T2DM patients have an increased risk of
developing AD [3, 4]. Due to its dual actions on tau
phosphorylation and aggregation, in chronic administra-
tion regimens, metformin may unpredictably impact the
development of tauopathy with undefined outcomes in
elderly diabetic patients at risk for AD. Our results indi-
cate that the effects of metformin on tau pathology
manifest at doses yielding serum concentrations consist-
ent with those of therapeutic dosing in humans [22].
Given the projected increase of prevalence of both dia-
betes and AD over the next decades [68, 69], further
studies are warranted to investigate the effects of metfor-
min on AD development, its contribution to the in-
creased risk of AD associated with T2DM and its
therapeutic potential for tau-related neurodegenerative
conditions. Conversely, from a long-term perspective,
our findings indicate that the effects of metformin on
tau phosphorylation and aggregation could be dissoci-
ated through chemical modifications and point to




The following primary antibodies were used: mouse
monoclonal antibodies against GSK3β (Millipore),
IRβ, S6 (Santa Cruz), βI-tubulin (Sigma), β-actin
(Sigma), caspase cleaved tau (Millipore), c-PARP, AKT
(pan), IRS1 (Cell Signaling), PSD95 (Cell Signaling for
Western blot or Millipore for immunocytochemistry),
Synapsin-I (Millipore), GFP (Roche) and Rheb (Santa
Cruz Biotechnologies); rabbit polyclonal antisera
against p[Ser1162/1165]IRβ, p[S9]GSK3β, AMPK,
p[T172]AMPK, PP2A, p[S240/244]S6, mTOR,
p[S2448]mTOR, p[S473]AKT, active cleaved caspase 3
(Cell Signaling), actin (Sigma) and p[S616]IRS1 (Invitro-
gen), Synaptophysin (Cell Signaling). For total tau and
phospho-tau analysis, we used the monoclonal antibodies
MC1 [36] and PHF1 [70] (kind gift of Dr P.Davies, Al-
bert Einstein College of Medicine, New York, NY),
AT100, AT270 (Autogen Bioclear), Tau5, AT8 (Calbio-
chem) and the polyclonal anti-p[S262]Tau antibody
(Invitrogen). Secondary antibodies conjugated with Alexa
fluorophores were from Invitrogen. For western blot ana-
lysis, horseradish-peroxidase (HRP)-conjugated second-
ary antibodies (Thermo Scientific) or ECL Plex Cy3-
conjugated goat anti-mouse IgG and Cy5-conjugated
goat anti-rabbit IgG (GE Healthcare) were used.
Stock solutions of metformin, phenformin (Sigma),
buformin (Santa Cruz) were prepared in water. Insulin
(Humulin R® U-500, 100 UI/ml, Eli Lilly), heparin (12–
15 kDa, 5000 UI/ml, Sirton Pharmaceuticals), rapamycin
(LC labs; 25 mM in Ethanol), dorsomorphin (25 mM in
DMSO), and okadaic acid (Sigma; 250 μM in DMSO)
were used for experiments in vitro. Unless otherwise
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specified, general reagents and chemicals were from
Sigma and cell culture reagents were from Invitrogen.
Animals and pharmacological treatments
Male homozygous P301S transgenic [18] and age-
matched C57/Bl6 wild type (WT) non-transgenic mice
were used. Animal health and comfort were veterinary-
controlled. Mice were housed in filtered cages in a
temperature-controlled room with a 12:12 h dark/light
cycle with ad libitum access to water and food. All animal
experiments were performed in full compliance with the
European Community Council directive dated 86/609/
EEC, the revised directive 2010/63/EU and were approved
by the Italian Ministry of Health and by IIT Animal
Facility Committee. At 4 weeks of age, P301S were
randomly assigned to treatment or control groups (12–
15 mice/group). Animals in the treatment group received
2 mg/ml metformin in the drinking water for 4 months as
previously described [60]. Drinking bottles were replen-
ished with fresh water or metformin solution every week.
The dose of metformin was equivalent to ≈ 300 mg/kg/day
and was selected based on pharmacokinetic studies of
metformin distribution in rodents [71] and initial pharma-
cokinetic analyses in WT and P301S mice treated for
7 days with metformin. In rats, chronic administration of
such dose achieves plasma levels (7.6 μmol/l) [71] com-
parable to those obtained by therapeutic dosing in
humans (7.8 ÷ 23.3 μmol/l) [22] and yields similar levels
in the frontal cortex (4.3 ± 1.0 nmol/g of tissue) and
hippocampus (4.3 ± 0.7 nmol/g) [71]. Using HPLC-MS
analysis as in [71], we measured the concentration of met-
formin in plasma and brain of WTand P301S mice treated
for 7 days. Metformin concentration in plasma was in the
low micromolar range and was similar in WT and P301S
mice treated for 7 days (Additional file 1: Table S1). Levels
of metformin in the brain were also comparable in WT
and P301S mice (Additional file 1: Table S1). In untreated
WT and P301S mice, metformin was undetectable in
plasma and brain. Levels of metformin were also deter-
mined in the plasma of P301S mice treated for 4 months.
After chronic treatment, plasma levels of metformin
(μmol/l ± SD, 0.7 ± 0.4, n = 6) were similar to those
achieved by 7 day administration (Additional file 1:
Table S1). During chronic administration with metfor-
min, body weight, glycemia, water and food consump-
tion were monitored weekly. Glycemia, water and
food consumption were unaffected by metformin
(Additional file 1: Figure S4). In P301S mice, body
weight steadily increased from 1 to 4 months of age.
From 4 months of age, the body weight stops increas-
ing (Additional file 1: Figure S4A), because of pro-
gressive muscle atrophy [18]. Metformin treatment
did not significantly influence body weight.
Intraperitoneal glucose tolerance test and insulin
tolerance test
For IPGTT, after fasting overnight for 16 h, 5-month old
mice were challenged by intraperitoneal injection of
2 g/kg glucose bolus. For ITT, mice were adapted by
intraperitoneal saline solution injection for 3 days.
After fasting for 6 h, mice were injected intraperito-
neally with 0.5 UI/kg insulin. Blood samples were
drawn from tail nicks over a 2 h period at selected time
intervals. Blood glucose content was measured by using
GlucoCards and the GlucoCard G Meter (A.Menarini),
following the manufacturer’s instructions.
Glucose and insulin assays
Glucose was measured using the Amplex red glucose
assay kit (Invitrogen) following the manufacturer’s in-
structions. Mouse hemi-cortices were lysed in 20 mM
Tris HCl pH 7.5, 150 mM NaCl 1 mM EDTA, 1 mM
EGTA, 1 % Triton X-100, and phosphatases and pro-
teases inhibitors by trituration using a glass-glass
dounce tissue homogenizer on ice. Lysates were spun
at 30,000 x g using a Beckman Optima Ultra Centrifuge
and the MLA 130 Rotor for 30 min at 4 °C. The
supernatant was collected for glucose measurement
with Amplex red. The fluorescence values were read
at 545 nm excitation and 590 nm emission wave-
lengths using a Victor 3 Multi-label Microplate Reader
(Perkin Elmer).
Cortical insulin content was measured using a specific
sandwich ELISA for mouse insulin (Millipore) following
the manufacturer’s instructions.
Behavioral tests
Hind limb extension test
The hind limb extension test [40] was performed weekly
for the entire treatment period. Mice were held at the
tip of the tail and suspended 30 cm above the floor for
20 s. Mice were scored from 0–5 based on the degree of
hindlimb extension reflex or the presence of paw clasp-
ing. An animal received a score of 0 when the leg exten-
sion reflex was normal. Score 1 and 2 were assigned
when mice retracted the hindlimbs after 15 or 5 s, re-
spectively. Score 3 and 4 were given when mice showed
asymmetric retraction of one leg (score 3) or both legs
(score 4) from the beginning of the test. Mice scored 5
when hindlimbs were completely retracted towards the
body and paws were clasped for the entire test time.
Open-field
The open field protocol was adapted from [20].
Briefly, at 17–18 weeks of age, all mice underwent a
single 20 min trial session of open-field testing. Mice
were first acclimated to the room for 15 min the
same day of testing. To start the test, each animal
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was placed facing the wall in an open-field arena
(44 cm L × 44 cm W× 44 cm H) made of black plexi-
glass, with a light grey bottom. Behavioral perform-
ance was recorded using a video tracking system
(Any-Maze; Ugo Basile, Varese, Italy). Behavioral ana-
lyses were carried out on recorded movies using the
AnyMaze software (Stoelting). The same observer,
who was unaware of the animals’ genotype, assigned
all scores. The 20-min trial session was divided into
four blocks (sessions) of 5 min each. During the 20-min
session, the frequency of the following behavioral pa-
rameters was scored: traveled distance, speed, time in
the center, and jumping (only frequency). During the
central 10 min test phase (2nd-3rd 5-min sessions),
the following behavioral parameters were scored: wall
rearing, standing on the hindlimbs and touching the
walls of the apparatus with the forelimbs; rearing,
standing on the hindlimbs in the open (away from
the walls of the apparatus); grooming, licking and
mouthing its own fur, sometimes with the help of the
forepaws.
Primary neuronal cultures and pharmacological treatment
Primary cortical neurons were isolated from the brain of
WT embryos of either sex at E18 as previously described
[72]. Embryonic cortices were collected in DMEM, and
cells were dissociated by incubation with trypsin/EDTA
at 37 °C. Cells were then diluted in neurobasal medium
containing B27 supplement, Glutamax, penicillin/
streptomycin and plated at a density of 7.0 × 105 cells/
well on 6-well plates coated with 0.1 mg/ml poly-L-
lysine (PLL; Sigma). Neurons were cultured at 37 °C in a
humidified incubator with 5 % CO2. After 6 days, the
medium was replaced with medium containing B27
without insulin. Twenty-four hours later, neurons were
incubated with or without 2.5 mM metformin, 30 μM
phenformin, 30 μM buformin, 10 μM rapamycin, 10 μM
dorsomorphin and/or 10 nM okadaic acid for 6 h. Alter-
natively, neurons were incubated with or without
0.5 mM metformin for 24 h as indicated in selected ex-
periments. In selected experiments, neurons were main-
tained in medium containing B27 with insulin for the
entire treatment period. After pharmacological treat-
ments, neuronal viability was assessed using the MTT
assay as described elsewhere [72]. None of the pharma-
cological treatments altered the viability of neurons over
6 h (Additional file 1: Table S2).
Cortical neurons transduction with lentiviral particles
Lentiviral plasmids pHAGE-CMV-Rheb(S16H)-IRES-
eGFP-W [73] and pHAGE-CMV-IRES-eGFP-W [74]
were obtained by Addgene and verified by DNA sequen-
cing. Lentiviral particles were produced according to
[75]. Neurons were plated at a density of 5 × 105 /well
onto PLL-coated 6-well plates, incubated at 37 °C with
5 % CO2 for 4 days and then transduced with 10 MOI of
lentiviral particles for 24 h. Six days after infection, the
medium was replaced and after 24 h neurons were
treated for 6 h with 2.5 mM metformin.
Western blots
Brain tissues or primary cortical neurons were sonicated
in 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA,
0.5 % Triton X-100, and protease and phosphatase in-
hibitors and incubated for 30 min on ice. Samples
were spun at 20,800 x g in an Eppendorf 5417R cen-
trifuge for 45 min. Supernatants were collected and
protein concentration was determined using the BCA
kit (Pierce).
Equal amount of proteins were separated by electro-
phoresis on 10 % SDS-PAGE as previously described
[76] and transferred overnight at 4 °C onto Protran 0.2
NC nitrocellulose membranes (Amersham). Membranes
were blocked for 1 h at room temperature with 5 % non-
fat milk or bovine serum albumin (BSA) in blocking buf-
fer containing 0.05 % Tween-20 in phosphate buffered
saline (PBS) pH 7.4 and incubated overnight at 4 °C with
primary antibodies. Membranes were rinsed in Tris buff-
ered saline pH 7.4 with 0.05 % Tween 20 (TBST) and in-
cubated for 1 h at room temperature with secondary
antibodies. Chemiluminescent signals were visualized
using the SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific) and acquired using Image
Quant LAS 4000 mini (GE Healthcare). Fluorescent sig-
nals were acquired using Typhoon Trio + and Typhoon
Scanner Control v5.0 software (GE Healthcare). Densito-
metric analysis was performed using ImageJ software
[77]. Protein levels were normalized on βI-tubulin or
actin. Phosphorylated proteins were normalized to
the respective total protein. Data were expressed as
percentage of WT untreated mice unless otherwise
specified.
RNA isolation and quantitative real time PCR (qRT-PCR)
RNA was isolated using the Qiazol extraction protocol
with 5 PRIME Phase lock Gel Tubes (Fisher Scientific)
according to the manufacturer’s protocol. RNA was
quantified using an ND1000 Nanodrop spectrophotom-
eter (NanoDrop Technologies, Inc). Reverse transcrip-
tion of 1 μg of RNA was performed using the RT2 First
Strand Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. qRT-PCR was performed
using the QuantiFast SYBR Green PCR Kit (Qiagen) on
a 7900HT Real-time System Instrument equipped with
Sequence Detection Systems 2.3 Software (Applied
Biosystem) as previously described [72]. Data were
normalized to the expression of multiple housekeep-
ing genes, including actin, GAPDH and HPRT1, as
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described [72], and Ct values were converted into fold-
expression values relative to control using qBasePLUS soft-
ware (Biogazelle). Primers are listed in Additional file 1:
Table S3.
Immunocytochemistry
Neurons were fixed in 4 % paraformaldehyde (PFA),
permeabilized, blocked in 5 % BSA and then incubated
overnight at 4 °C with anti-synapsin-I and PSD95 anti-
bodies in BSA. Specimens were visualized under a
Decon microscope (Axio Observer Z1, ZEISS).
Immunohistochemistry and confocal microscopy
Mice were deeply anesthetized with 20 % urethane in sa-
line and transcardially perfused with saline followed by
4 % PFA in PBS. Brains were then dissected, post-fixed
in 4 % PFA for 24 h at 4 °C and cryopreserved in 30 %
sucrose in PBS for 24 h. 30 μm sections were cut using a
Microm HM450 sliding microtome (BioOptica). Immu-
nohistochemical detection of tau and phospho-tau was
performed as described [76] using sagittal sections col-
lected from −0.48 to −1.32 mm from bregma. Insoluble
aggregates with β-sheet conformation were detected by
Gallyas silver staining or staining with the Congo red
analogue FSB (DojinDo Laboratories) [78] as previously
described [76]. Hoechst-33342 (Sigma) was used to stain
nuclei. For cell counts, fluorescence images of entire sec-
tions were collected using an automated Olympus BX51
microscope, equipped with a MBF Optonic CX9000
camera, UPLFLN SEMIAPO FLUORITE 10X NA ob-
jective and MBF Neurolucida V11 software. An experi-
enced researcher blind to the nature of the samples
counted the numbers of AT8-, Gallyas- and FSB-positive
cells. 3–5 slices were analyzed per animal. Cell counts
were normalized to the area of the respective brain
region.
Confocal optical sectioning was performed with 1 μm
step using an inverted Confocal Leica TCS SP5 AOBS
TANDEM Leica Las AF equipped with an HCX PL APO
40X 1.25 NA oil objective.
Tau purification and aggregation
Recombinant tau was produced as described previously
[79]. Briefly, the cDNA of the 441-amino acid isoform of
human brain tau (2 N, 4R) was cloned in the pET-21
plasmid and expressed in Escherichia coli BL21 (DE3).
Cultures were grown to mid-log phase and isopropyl-1-
thio-β-D-galactopyranoside was added to 400 μM. After
4 h shaking at 220 rpm at 30 °C, cells were pelleted,
lysed in 50 mM PIPES pH 6.8 by boiling for 5 min,
placed on ice, and 1 mM DTT was added. The lysate
was spun at 38,000 x g for 1 h at 4 °C. The supernatant
was collected, subjected to ion exchange chromatog-
raphy using HITRAP CM FF (GE Healthcare), eluted in
50 mM PIPES pH 6.8 and a gradient of NaCl (up to
0.5 M). Fractions were run on a 10 % Tris-glycine gel
and stained with Comassie to examine recombinant
tau. Tau-containing fractions were pooled, chromato-
graphed on a Superdex-75 size exclusion column (GE
Healthcare) and eluted in 25 mM Tris-HCl, pH 7.4.
The absorbance at 220 and 280 nm was measured to
determine the concentration of the freshly purified
protein. Purified recombinant protein stocks were stored
in aliquots at −80 °C until use.
Purified recombinant tau (50 μM), 37.5 μM heparin
(molar ratio tau/heparin = 0.75) and/or 30 μM metfor-
min, buformin or phenformin were incubated at 37 °C
for 8–15 days in PBS pH 7.4, containing 1 mM EDTA
and 1 mM EGTA. Tau aggregation was monitored using
the Thioflavin T (ThT; Sigma) assay. Sample fluores-
cence was examined using a Tecan Infinite plate reader
set at 430 nm for excitation and 485 nm for emission.
Tau aggregates were also analyzed by western blot and
transmission electron microscopy.
Sarkosyl extraction
Sarkosyl-insoluble tau was extracted as described previ-
ously [76]. Briefly, tissues were homogenized in 10 vol-
umes of cold extraction buffer (10 mM Tris-HCl,
pH 7.4, 0.8 M NaCl, 1 mM EGTA, 10 % sucrose) and
the homogenates were spun for 30 min at 20,000 × g.
After adding 1 % sarkosyl, the samples were shaken for
1 h at room temperature and spun at 100,000 × g for 1 h
at 4 °C. The pellets containing insoluble tau were resus-
pended in 50 mM Tris-HCl, pH 7.4 and stored at 4 °C
until analysis by western blot.
Negative staining transmission electron microscopy
Recombinant tau protein aggregates were placed onto
300-mesh glow discharged carbon-coated grids and
negatively stained in 2 % uranyl acetate. The samples
were observed with a FEI Tecnai F20 field emission gun
transmission electron microscope (FEI Company, The
Netherlands), working at an acceleration voltage of
80 keV and equipped with a 2k X 2K Gatan Ultrascan
CCD camera (Gatan company, USA).
Statistical analysis
Statistical analysis of groups with normal distributions
was performed using the Student’s t-test for two groups
or ANOVA for multiple comparisons. One-way ANOVA
or two-way ANOVA followed by multiple comparisons
with the Holm-Sidak method was performed for more
than two groups. Differences among groups were consid-
ered statistically significant when p < 0.05. Data through-
out the text are reported as average values ± SEM unless
otherwise specified.
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